antibiotics

Paratek caps 20-year R&D journey with FDA OK for its broad spectrum antibiotic — time to talk launch
Paratek caps 20-year R&D journey with FDA OK for its broad spectrum antibiotic — time to talk launch
Endpoints
antibiotics
FDA
R&D
Paratek
Nuzyra
Flag link:
MicuRx Recieves Fast Track and QIDP Designations for MRSA Antiobiotics
MicuRx Recieves Fast Track and QIDP Designations for MRSA Antiobiotics
CP WIre
MicuRx Pharmaceuticals
MRX-1
contezolid
contezolid acefosamil
antibiotics
MRSA
Flag link:
MicuRx Recieves Fast Track and QIDP Designations for MRSA Antiobiotics
MicuRx Pharmaceuticals
MRX-1
contezolid
contezolid acefosamil
antibiotics
MRSA
Flag link:
Boehringer Ingelheim and Tsinghua University Collaborate to Harness the Immune System to Better Fight Infectious Diseases
Boehringer Ingelheim and Tsinghua University Collaborate to Harness the Immune System to Better Fight Infectious Diseases
CP Wire
antibiotics
Boehringer Ingelheim
drug development
Flag link:
Tetraphase Pharma’s Antibiotic Wins FDA Approval for Gut Infections
Tetraphase Pharma’s Antibiotic Wins FDA Approval for Gut Infections
Xconomy
Tetraphase Pharmaceuticals
Xerava
FDA
antibiotics
cIAI
complicated intra-abdominal infections
Flag link:
Paratek clears one last big hurdle on the way to an FDA marketing decision for antibiotic
Paratek clears one last big hurdle on the way to an FDA marketing decision for antibiotic
Endpoints
Paratek
antibiotics
omadacycline
FDA
advisory panels
Flag link:
Paratek antibiotic not inferior to current treatments: FDA staff
Paratek antibiotic not inferior to current treatments: FDA staff
Reuters
Paratek
antibiotics
FDA
aminomethylcyclines
Flag link:
Urgent care centers often prescribe unnecessary antibiotics
Urgent care centers often prescribe unnecessary antibiotics
Reuters
antibiotics
antibiotic resistance
urgent care
physicians
Flag link:
Taking on biodefense threats, antibiotics maker Spero inks $54M in government deals
Taking on biodefense threats, antibiotics maker Spero inks $54M in government deals
Endpoints
Spero
antibiotics
biodefense drugs
defense contracts
Flag link:
Novartis joins the Big Pharma exodus out of antibiotics, dumping research, cutting 140 and out-licensing programs
Novartis joins the Big Pharma exodus out of antibiotics, dumping research, cutting 140 and out-licensing programs
Endpoints
Novartis
R&D
antibiotics
antivirals
layoffs
Flag link:
As drug resistance grows, combining antibiotics could turn up new treatments
As drug resistance grows, combining antibiotics could turn up new treatments
Stat
antibiotics
antibiotic resistance
drug development
Flag link:
It's a good news, bad news FDA approval for Achaogen's powerful antibiotic Zemdri
It's a good news, bad news FDA approval for Achaogen's powerful antibiotic Zemdri
Fierce Pharma
Achaogen
FDA
Zemdri
antibiotics
UTIs
Flag link:
UTILITY Therapeutics Inks License Agreement for Two Antibiotics for the US Market
UTILITY Therapeutics Inks License Agreement for Two Antibiotics for the US Market
CP Wire
UTILITY Therapeutics
antibiotics
LEO Pharma
Flag link:
Phage-Based Therapy - A Primer
Phage-Based Therapy - A Primer
CP Wire
phages
bacteriophage
antibiotics
antibiotic resistance
Flag link:
Phage-Based Therapy - A Primer
phages
bacteriophage
antibiotics
Flag link:
Arrevus Receives NIH Fast-Track Grant to Develop ARV-1502 Against Multi-Drug Resistant Bacteremia
Arrevus Receives NIH Fast-Track Grant to Develop ARV-1502 Against Multi-Drug Resistant Bacteremia
CP Wire
Arrevus
antibiotics
ARV-1502
bacterenua
antibiotic resistance
Flag link:
J&J dumps a failed PhIII antibiotic program picked up in Actelion buyout
J&J dumps a failed PhIII antibiotic program picked up in Actelion buyout
Endpoints
JNJ
Actelion
antibiotics
C. difficile
cadazolid
Flag link:
Nosopharm and University of Chicago Researchers Report on New Class of Antibiotics
Nosopharm and University of Chicago Researchers Report on New Class of Antibiotics
CP Wire
Nosopharm
antibiotics
drug development
Flag link:
Genentech antibody spotlights new target for antibiotic-resistant bacteria
Genentech antibody spotlights new target for antibiotic-resistant bacteria
Fierce Biotech
Genentech
antibiotic resistance
antibiotics
R&D
drug discovery
BamA enzyme
Flag link:
After 20 years, Paratek’s broad-spectrum antibiotic is headed to the FDA
After 20 years, Paratek’s broad-spectrum antibiotic is headed to the FDA
Drug Delivery Business News
Paratek
antibiotics
broad spectrum antibiotics
FDA
omadacycline
Flag link:

Pages